日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial

新辅助帕博利珠单抗治疗IV期高级别浆液性卵巢癌:II期Neo-Pembro试验

S L Aronson ,B Thijssen ,M Lopez-Yurda ,S N Koole ,P van der Leest ,A León-Castillo ,R Harkes ,I M Seignette ,J Sanders ,M Alkemade ,I Kemper ,M J Holtkamp ,I A M Mandjes ,A Broeks ,M J Lahaye ,M A Rijlaarsdam ,D van den Broek ,L F A Wessels ,H M Horlings ,W J van Driel ,G S Sonke

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial

早期三阴性乳腺癌新辅助治疗:纳武利尤单抗或纳武利尤单抗联合伊匹木单抗:一项 II 期适应性试验

Iris Nederlof # ,Olga I Isaeva # ,Manon de Graaf ,Robbert C A M Gielen ,Noor A M Bakker ,Adrianne L Rolfes ,Hannah Garner ,Bram Boeckx ,Joleen J H Traets ,Ingrid A M Mandjes ,Michiel de Maaker ,Thomas van Brussel ,Maksim Chelushkin ,Elisa Champanhet ,Marta Lopez-Yurda ,Koen van de Vijver ,José G van den Berg ,Ingrid Hofland ,Natasja Klioueva ,Ritse M Mann ,Claudette E Loo ,Frederieke H van Duijnhoven ,Victoria Skinner ,Sylvia Luykx ,Emile Kerver ,Ekaterina Kalashnikova ,Marloes G J van Dongen ,Gabe S Sonke ,Sabine C Linn ,Christian U Blank ,Karin E de Visser ,Roberto Salgado ,Lodewyk F A Wessels ,Caroline A Drukker ,Ton N Schumacher ,Hugo M Horlings ,Diether Lambrechts ,Marleen Kok

Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial

MATADOR试验中预测乳腺癌辅助紫杉烷类药物疗效的基因表达谱

Opdam, Mark; van Rossum, Annelot G J; Hoogstraat, Marlous; Bounova, Gergana; Horlings, Hugo M; van Werkhoven, Erik; Mandjes, Ingrid A M; van Leeuwen-Stok, A Elise; Canisius, Sander; van Tinteren, Harm; Imholz, Alex L T; Portielje, Johanneke E A; Bos, Monique E M M; Bakker, Sandra; Wesseling, Jelle; Kester, Lennart; van Rheenen, Jacco; Rutgers, Emiel J; de Menezes, Renee X; Wessels, Lodewyk F A; Kok, Marleen; Oosterkamp, Hendrika M; Linn, Sabine C

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial

PD-L1阻断联合卡铂作为转移性小叶癌的免疫诱导疗法:GELATO试验

Voorwerk, Leonie; Isaeva, Olga I; Horlings, Hugo M; Balduzzi, Sara; Chelushkin, Maksim; Bakker, Noor A M; Champanhet, Elisa; Garner, Hannah; Sikorska, Karolina; Loo, Claudette E; Kemper, Inge; Mandjes, Ingrid A M; de Maaker, Michiel; van Geel, Jasper J L; Boers, Jorianne; de Boer, Maaike; Salgado, Roberto; van Dongen, Marloes G J; Sonke, Gabe S; de Visser, Karin E; Schumacher, Ton N; Blank, Christian U; Wessels, Lodewyk F A; Jager, Agnes; Tjan-Heijnen, Vivianne C G; Schröder, Carolien P; Linn, Sabine C; Kok, Marleen

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial

通过联合使用莫那珠单抗和曲妥珠单抗激活NK细胞和CD8 T细胞治疗转移性HER2阳性乳腺癌:MIMOSA试验结果

Geurts, V C M; Voorwerk, L; Balduzzi, S; Salgado, R; Van de Vijver, K; van Dongen, M G J; Kemper, I; Mandjes, I A M; Heuver, M; Sparreboom, W; Haanen, J B A G; Sonke, G S; Horlings, H M; Kok, M

High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial

高剂量烷化剂化疗治疗 BRCA 基因突变的三阴性乳腺癌:随机 III 期 NeoTN 试验

Vliek, Sonja; Hilbers, Florentine S; van Werkhoven, Erik; Mandjes, Ingrid; Kessels, Rob; Kleiterp, Sieta; Lips, Esther H; Mulder, Lennart; Kayembe, Mutamba T; Loo, Claudette E; Russell, Nicola S; Vrancken Peeters, Marie-Jeanne T F D; Holtkamp, Marjo J; Schot, Margaret; Baars, Joke W; Honkoop, Aafke H; Vulink, Annelie J E; Imholz, Alex L T; Vrijaldenhoven, Suzan; van den Berkmortel, Franchette W P J; Meerum Terwogt, Jetske M; Schrama, Jolanda G; Kuijer, Philomeen; Kroep, Judith R; van der Padt-Pruijsten, Annemieke; Wesseling, Jelle; Sonke, Gabe S; Gilhuijs, Kenneth G A; Jager, Agnes; Nederlof, Petra; Linn, Sabine C

Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments

乳腺癌患者的生存率和治疗获益差异是由不同的上皮细胞和免疫细胞微环境决定的。

Kester, Lennart; Seinstra, Danielle; van Rossum, Annelot G J; Vennin, Claire; Hoogstraat, Marlous; van der Velden, Daphne; Opdam, Mark; van Werkhoven, Erik; Hahn, Kerstin; Nederlof, Iris; Lips, Ester H; Mandjes, Ingrid A M; van Leeuwen-Stok, A Elise; Canisius, Sander; van Tinteren, Harm; Imholz, Alex L T; Portielje, Johanneke E A; Bos, Monique E M M; Bakker, Sandra D; Rutgers, Emiel J; Horlings, Hugo M; Wesseling, Jelle; Voest, Emile E; Wessels, Lodewyk F A; Kok, Marleen; Oosterkamp, Hendrika M; van Oudenaarden, Alexander; Linn, Sabine C; van Rheenen, Jacco

Statistical inference for a quasi birth-death model of RNA transcription

RNA转录准生灭模型的统计推断

de Gunst, Mathisca; Mandjes, Michel; Sollie, Birgit

Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature

限制对70基因特征超低分级的绝经后乳腺癌患者进行全身内分泌过度治疗

Opdam, M; van der Noort, V; Kleijn, M; Glas, A; Mandjes, I; Kleiterp, S; Hilbers, F S; Kruger, D T; Bins, A D; de Jong, P C; Schiphorst, P P J B M; van Dalen, T; Flameling, B; Rietbroek, R C; Beeker, A; van den Heiligenberg, S M; Bakker, S D; Wymenga, A N M; Oving, I M; Bijlsma, R M; van Diest, P J; Vermorken, J B; van Tinteren, H; Linn, S C

Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial

ERBB2 阳性乳腺癌患者接受新辅助化疗(含或不含蒽环类药物)联合双重 ERBB2 阻断治疗的三年随访:TRAIN-2 随机 3 期试验的二次分析

van der Voort, Anna; van Ramshorst, Mette S; van Werkhoven, Erik D; Mandjes, Ingrid A; Kemper, Inge; Vulink, Annelie J; Oving, Irma M; Honkoop, Aafke H; Tick, Lidwine W; van de Wouw, Agnes J; Mandigers, Caroline M; van Warmerdam, Laurence J; Wesseling, Jelle; Vrancken Peeters, Marie-Jeanne T; Linn, Sabine C; Sonke, Gabe S